Quick Answer
Autolus Therapeutics plc reported Cash and Equivalents of $104.13 million for fiscal year 2025.
Autolus Therapeutics plc Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $104.13M | -54.2% |
| 2024 | $227.38M | -5.1% |
| 2023 | $239.57M | -6.6% |
| 2023 | $256.42M | -16.6% |
| 2023 | $307.50M | -10.4% |
| 2023 | $343.03M | -10.3% |
| 2022 | $382.44M | +134.5% |
| 2022 | $163.05M | -24.7% |
| 2022 | $216.44M | -19.4% |
| 2022 | $268.56M | -13.5% |
| 2021 | $310.34M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $86.12M | -86.9% | -30.4% |
| June 30, 2025 | $123.83M | -82.5% | +29.3% |
| March 31, 2025 | $95.80M | -87.4% | -57.9% |
| December 31, 2024 | $227.38M | -5.1% | -65.4% |
| September 30, 2024 | $657.07M | +156.3% | -6.9% |
| June 30, 2024 | $705.94M | +129.6% | -6.9% |
| March 31, 2024 | $758.53M | +121.1% | +216.6% |
| December 31, 2023 | $239.57M | -37.4% | -6.6% |
- Autolus Therapeutics plc showed a decrease of -54.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2021–2025 period, Autolus Therapeutics plc’s cash and equivalents has declined by 66.4% (from $310.34 million to $104.13 million).
- The most recent figure is from Autolus Therapeutics plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: